ArticlePloS one2014
Expanded HIV testing in low-prevalence, high-income countries: a cost-effectiveness analysis for the United Kingdom.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- The impact of nurse-driven targeted HIV screening in 8 emergency departments: study protocol for the DICI-VIH cluster-randomized two-period crossover trial.BMC infectious diseases · 2016Trial
- HIV testing trend and associated factors among people who inject drugs in Iran (2010-2020).Harm reduction journal · 2026Article
- Epidemiological yield and cost-effectiveness of non-targeted community HIV screening in a low-prevalence district: a prospective quasi-experimental study.Frontiers in public health · 2026Article
- Article
- Embedding patient and public involvement into a doctoral study: developing a point-of-care HIV testing intervention for dental settings.Frontiers in oral health · 2024Article
- A multimorbidity model for estimating health outcomes from the syndemic of injection drug use and associated infections in the United States.BMC health services research · 2023Article
- Article
- The Cost-Effectiveness of HIV/STI Prevention in High-Income Countries with Concentrated Epidemic Settings: A Scoping Review.AIDS and behavior · 2022Article
- A survey of the involvement of primary care doctors in HIV prevention and care in a low-prevalence, high-income setting.BMC family practice · 2021Article
- Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review.PharmacoEconomics · 2019Review
- Developing a dynamic HIV transmission model for 6 U.S. cities: An evidence synthesis.PloS one · 2019Article
- Evidence for optimal HIV screening and testing intervals in HIV-negative individuals from various risk groups: A systematic review.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2018Article
- Building the Case for Localized Approaches to HIV: Structural Conditions and Health System Capacity to Address the HIV/AIDS Epidemic in Six US Cities.AIDS and behavior · 2018Review
- Cost-effectiveness of screening for HIV in primary care: a health economics modelling analysis.The lancet. HIV · 2017Article
- Creating impact with operations research in health: making room for practice in academia.Health care management science · 2016Article
- Modeling and Cost-Effectiveness in HIV Prevention.Current HIV/AIDS reports · 2016Review
- Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM.AIDS (London, England) · 2015Article
- Premarital examination and counseling: Impact on HIV knowledge among Jordanian women-A national survey analysis.Women's health (London, England)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveIn many high-income countries with low HIV prevalence, significant numbers of persons living with HIV (PLHIV) remain undiagnosed. Identification of PLHIV via HIV testing offers timely access to lifesaving antiretroviral therapy (ART) and decreases HIV transmission. We estimated the effectiveness and cost-effectiveness of HIV testing in the United Kingdom (UK), where 25% of PLHIV are estimated to be undiagnosed.
designWe developed a dynamic compartmental model to analyze strategies to expand HIV testing and treatment in the UK, with particular focus on men who have sex with men (MSM), people who inject drugs (PWID), and individuals from HIV-endemic countries.
methodsWe estimated HIV prevalence, incidence, quality-adjusted life years (QALYs), and health care costs over 10 years, and cost-effectiveness.
resultsAnnual HIV testing of all adults could avert 5% of new infections, even with no behavior change following HIV diagnosis because of earlier ART initiation, or up to 18% if risky behavior is halved. This strategy costs £67,000-£106,000/QALY gained. Providing annual testing only to MSM, PWID, and people from HIV-endemic countries, and one-time testing for all other adults, prevents 4-15% of infections, requires one-fourth as many tests to diagnose each PLHIV, and costs £17,500/QALY gained. Augmenting this program with increased ART access could add 145,000 QALYs to the population over 10 years, at £26,800/QALY gained.
conclusionsAnnual HIV testing of key populations in the UK is very cost-effective. Additional one-time testing of all other adults could identify the majority of undiagnosed PLHIV. These findings are potentially relevant to other low-prevalence, high-income countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.